Overview of the INPRO Project

During the last fifty years remarkable results are achieved in the application of nuclear technology for the production of electricity. Looking ahead to the next fifty years it is clear that the demand for energy will grow considerably and also the requirements for the way the energy will be supplied. Within the International Project on Innovative Nuclear Reactors and Fuel Cycles (INPRO), the future of the energy demand and supply was explored and several scenario's identified. A leading requirement for energy supply is coming up and will play a crucial role: sustainability of the way the energy supply will be realized. Fulfilling the growing need for energy in developing countries is as well an important issue. Based on these scenario's for the next fifty years, an inventory of requirements for the future of nuclear energy systems has been collected as well a methodology developed by INPRO to assess innovative nuclear systems and fuel cycles. On the base of this assessment, the need for innovations and breakthroughs in existing technology can be defined. To facilitate the deployment of innovative nuclear systems also the infrastructure, technical as well as institutional has to be adjusted to the anticipated changes in the world such as the globalization. As a contribution to the conference the main messages of INPRO will be presented

Matter-Antimatter Asymmetry - Aspects at Low Energy

The apparent dominance of matter over antimatter in our universe is an obvious and puzzling fact which cannot be adequately explained in present physical frameworks that assume matter-antimatter symmetry at the big bang. However, our present knowledge of starting conditions and of known sources of CP violation are both insufficient to explain the observed asymmetry. Therefore ongoing research on matter-antimatter differences is strongly motivated as well as attempts to identify viable new mechanisms that could create the present asymmetry. Here we concentrate on possible precision experiments at low energies towards a resolution of this puzzle.Comment: 6 pages, 1 figure; accepted for publication in Annalen der Physik (2015

Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma

There is no established second-line treatment for advanced pancreatic cancer after gemcitabine failure. In view of the urgent need for such therapy, and since preclinical and phase I clinical data suggest an encouraging, potentially synergistic activity between raltitrexed and irinotecan, the present randomised phase II study was initiated. A total of 38 patients with metastatic pancreatic adenocarcinoma, who progressed while receiving or within 6 months after discontinuation of palliative first-line chemotherapy with gemcitabine, were enrolled in this study. They were randomised to 3-weekly courses of raltitrexed 3 mg m−2 on day 1 (arm A) or irinotecan 200 mg m−2 on day 1 plus raltitrexed 3 mg m−2 on day 2 (arm B). The primary study end point was objective response, secondary end points included progression-free survival (PFS) and overall survival (OS), as well as clinical benefit response in symptomatic patients (n=28). In the combination arm, the IRC-confirmed objective response rate was 16% (three out of 19 patients had a partial remission; 95% CI, 3–40%), which was clearly superior to that in the comparator/control arm with raltitrexed alone, in which no response was obtained. Therefore, the trial was already stopped at the first stage of accrual. Also, the secondary study end points, median PFS (2.5 vs 4.0 months), OS (4.3 vs 6.5 months), and clinical benefit response (8 vs 29%) were superior in the combination arm. The objective and subjective benefits of raltitrexed+irinotecan were not negated by severe, clinically relevant treatment-related toxicities: gastrointestinal symptoms (42 vs 68%), partial alopecia (0 vs 42%), and cholinergic syndrome (0 vs 21%) were more commonly noted in arm B; however, grade 3 adverse events occurred in only three patients in both treatment groups. Our data indicate that combined raltitrexed+irinotecan seems to be an effective salvage regimen in patients with gemcitabine-pretreated pancreatic cancer. The superior response activity, PFS and OS (when compared to raltitrexed), as well as its tolerability and ease of administration suggest that future trials with this combination are warranted